|
|
| | C16 Lactosylceramide-d3 (d18:1/16:0-d3) Basic information |
| | C16 Lactosylceramide-d3 (d18:1/16:0-d3) Chemical Properties |
| solubility | Chloroform:
Methanol:
Water: (5:1:0.1): soluble |
| | C16 Lactosylceramide-d3 (d18:1/16:0-d3) Usage And Synthesis |
| Description | C16 Lactosylceramide-d3 (d18:1/16:0-d3) is intended for use as an internal standard for the quantification of C16 lactosylceramide (Item No. 24352) by GC- or LC-MS. C16 Lactosylceramide is an endogenous bioactive sphingolipid.1 It forms membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs), suggesting a role in cell signaling. Plasma levels of C16 lactosylceramide are elevated in insulin-resistant cattle.2 C16 Lactosylceramide is also upregulated in a mouse model of Niemann-Pick type C1 disease, a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder.3 As this product is derived from a natural source, there may be variations in the sphingoid backbone. [Matreya, LLC. Catalog No. 1534]WARNING This product is not for human or veterinary use. | | References | [1] K. IWABUCHI. Role of Ceramide from Glycosphingolipids and Its Metabolites in Immunological and Inflammatory Responses in Humans[J]. Mediators of Inflammation, 2015, 2015 1. DOI: 10.1155/2015/120748
[2] J.E. RICO . Plasma ceramides are elevated in overweight Holstein dairy cows experiencing greater lipolysis and insulin resistance during the transition from late pregnancy to early lactation[J]. Journal of Dairy Science, 2015, 98 11: Pages 7757-7770. DOI: 10.3168/jds.2015-9519
[3] MARIA PRAGGASTIS. A murine Niemann-Pick C1 I1061T knock-in model recapitulates the pathological features of the most prevalent human disease allele.[J]. Journal of Neuroscience, 2015, 35 21: 8091-8106. DOI: 10.1523/jneurosci.4173-14.2015 |
| | C16 Lactosylceramide-d3 (d18:1/16:0-d3) Preparation Products And Raw materials |
|